Patents by Inventor Andrew Michael Kenneth Pennell
Andrew Michael Kenneth Pennell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6740644Abstract: A compound of formula (I), wherein R2 represents C1-3alkyl, halogen or hydrogen; R3 represents straight or branched alkyl group of 1-6 carbon atoms; with the proviso that, when R3 represents C1-3alkyl, R2 represents C1-3alkyl, R1 cannot represent phenyl optionally substituted by one or more substituents selected from halogen, C1-3alkyl, trifluoromethyl, nitro, cyano, —CO2Rc, —CONRcRd, —CORc, —SORe, —SO2Re, —SO3H, —SO2NRcRd, —ORc, —NHSO2Re, —NHCORc and —NRcRd; and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof. These compounds are agonists at the Adenosine A1 receptor.Type: GrantFiled: February 26, 2003Date of Patent: May 25, 2004Assignee: Smithkline Beecham CorporationInventors: Colin David Eldred, Andrew Michael Kenneth Pennell
-
Patent number: 6677316Abstract: A method of treating a patient suffering from or susceptible to ischemic heart disease, peripheral vascular disease or stroke or which subject is suffering pain, a CNS disorder or sleep apnea which comprises administering a therapeutically effective amount of an adenosine derivative which is an agonist at the adenosine A1 receptor and which exhibits little or no agonist activity of the A3 receptor.Type: GrantFiled: August 13, 2002Date of Patent: January 13, 2004Assignee: SmithKline Beecham CorporationInventors: David Edmund Bays, Richard Peter Charles Cousins, Hazel Joan Dyke, Colin David Eldred, Brian David Judkins, Martin Pass, Andrew Michael Kenneth Pennell
-
Publication number: 20030158146Abstract: A compound of formula (I), wherein R2 represents C1-3alkyl, halogen or hydrogen; R3 represents straight or branched alkyl group of 1-6 carbon atoms; with the proviso that, when R3 represents C1-3alkyl, R2 represents C1-3alkyl, R1 cannot represent phenyl optionally substituted by one or more substituents selected from halogen, C1-3alkyl, trifluoromethyl, nitro, cyano, —CO2Rc, —CONRcRd, —CORc, —SORe, —SO2Re, —SO3H, —SO2NRcRd, —ORc, —NHSO2Re, —NHCORc and —NRcRd; and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof. These compounds are agonists at the Adenosine A1 receptor.Type: ApplicationFiled: February 26, 2003Publication date: August 21, 2003Applicant: SmithKline Beecham CorporationInventors: Colin David Eldred, Andrew Michael Kenneth Pennell
-
Publication number: 20030096788Abstract: A method of treating a patient suffering from or susceptible to ischemic heart disease, peripheral vascular disease or stroke or which subject is suffering pain, a CNS disorder or sleep apnea which comprises administering a therapeutically effective amount of an adenosine derivative which is an agonist at the adenosine A1 receptor and which exhibits little or no agonist activity of the A3 receptor.Type: ApplicationFiled: August 13, 2002Publication date: May 22, 2003Applicant: Glaxo Wellcome Inc.Inventors: David Edmund Bays, Richard Peter Charles Cousins, Hazel Joan Dyke, Colin David Eldred, Brian David Judkins, Martin Pass, Andrew Michael Kenneth Pennell
-
Patent number: 6544960Abstract: A compound of formula (I), wherein R2 represents C1-3alkyl, halogen or hydrogen; R3 represents straight or branched alkyl group of 1-6 carbon atoms; with the proviso that, when R3 represents C1-3alkyl, R2 represents C1-3alkyl, R1 cannot represent phenyl optionally substituted by one or more substituents selected from halogen, C1-3alkyl, trifluoromethyl, nitro, cyano, —CO2Rc, —CONRcRd, —CORc, —SORe, SO2Re, —SO3H, —SO2NRcRd, —ORc, —NHSO2Re, —NHCORc and —NRcRd; and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof. These compounds are agonists at the Adenosine Al receptor.Type: GrantFiled: June 15, 2000Date of Patent: April 8, 2003Assignee: SmithKline Beecham CorporationInventors: Colin David Eldred, Andrew Michael Kenneth Pennell
-
Patent number: 6492348Abstract: A compound of formula (I) which is an agonist at the adenosine Al receptor, wherein Y, Z, and W represent heteroatoms, and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof for use in therapy.Type: GrantFiled: March 6, 2001Date of Patent: December 10, 2002Assignee: SmithKline Beecham CorporationInventors: David Edmund Bays, Richard Peter Charles Cousins, Hazel Joan Dyke, Colin David Eldred, Brian David Judkins, Martin Pass, Andrew Michael Kenneth Pennell
-
Patent number: 6455510Abstract: A compound of formula (I) which is an agonist at the adenosine A1 receptor wherein R2 represents C1-3alkyl, halogen or hydrogen; R3 represents a fluorinated straight or branched alkyl group of 1-6 carbon atoms and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof. These compounds are agonists at the adenosine A1 receptor.Type: GrantFiled: June 15, 2000Date of Patent: September 24, 2002Assignee: SmithKline Beecham CorporationInventors: Richard Peter Charles, Brian Cox, Colin David Eldred, Andrew Michael Kenneth Pennell
-
Patent number: 6407076Abstract: A compound of formula (I) wherein R2 represents C1-3 alkyl, halogen or hydrogen; R3 represents a fluorinated straight or branched alkyl group of 1-6 carbon atoms; and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof. These compounds are agonists of the Adenosine A1 receptor.Type: GrantFiled: June 27, 2000Date of Patent: June 18, 2002Assignee: SmithKline Beecham CorporationInventors: Philip Charles Box, Brian David Judkins, Andrew Michael Kenneth Pennell
-
Patent number: 6020346Abstract: The present invention relates to piperidine derivatives of formula (I): ##STR1## wherein the substituents R.sup.1, R.sup.3, R.sup.4 and R.sup.5 are as defined in the specification and claims, and the substituent R.sup.2 is ##STR2## The pharmaceutically acceptable salts and solvates of these piperidine derivatives are also described. The invention also relates to processes for the preparation of the piperidine derivatives, and to their use in the treatment of conditions mediated by tachykinins.Type: GrantFiled: July 8, 1997Date of Patent: February 1, 2000Assignee: Glaxo Wellcome Inc.Inventors: Duncan Robert Armour, Gerard Martin Paul Giblin, Andrew Michael Kenneth Pennell, Peter John Sharratt
-
Patent number: 5998388Abstract: This invention relates to novel adenosine derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine. Thus the invention provides compounds of formula (I) which are agonists at the adenosine A1 receptor. ##STR1## wherein R.sup.1 represents phenyl optionally substituted by one or more substituents selected from halogen, C.sub.1-3 alkyl, trifluoromethyl, nitro, cyano, --CO.sub.2 R.sup.a.sub.1 --CONR.sup.a R.sup.b, --COR.sup.a, --SOR.sup.c, --SO.sub.2 R.sup.c, --SO.sub.3 H, --SO.sub.2 NR.sup.a R.sup.b, --OR.sup.a, --NHSO.sub.2 R.sup.c, --NHCOR.sup.a and --NR.sup.a R.sup.b,R.sup.2 represents a C.sub.1-6 alkyl or C.sub.3-6 alkenyl group; R.sup.3 represents C.sub.1-3 alkyl;R.sup.a and R.sup.b may each independently represent hydrogen or C.sub.1-3 alkyl or, when --NR.sup.a R.sup.b is directly attached to said phenyl, R.sup.a and R.sup.Type: GrantFiled: November 6, 1998Date of Patent: December 7, 1999Assignee: Glaxo Wellcome Inc.Inventors: Frank Ellis, Stephen Swanson, Richard Peter Charles, Brian Cox, Andrew Michael Kenneth Pennell, Colin David Eldred